Endo’s excellent altered presentations

Image Credit: Investors | Endo

Announcement 

Endo, a full-fledged subsidiary of Mallinckrodt plc, showcased a total of nine presentations based on XIAFLEX (collagenase clostridium histolyticum, injection 0.9 mg) and Peyronie’s disease or PD. The presentation will be projected during the sexual medicine society of North America (SMSNA) annual meeting that will be held on October 9-12, 2025. With this presentation, the meeting will bring change and a thoughtful development into the drug development for the concerned areas. The nine presentations are an excellent initiative, a preparation for next-generation medication for the improvement of men’s and women’s sexual health. It will be a support to the practice providers and existing professionals to decode the crucial area to pave solutions and effectiveness in the advancement of the existing and new drugs with accurate detailing.

The MD, urologist and presenting author of three of the presentations, Jesse N. Mills, said, “I’m excited to contribute to the medical community and have a chance to closely look at Peyronie’s disease, which is common but neglected. I hope that the providers at SMSNA will come together to help their patients with the required educational details that involve these current insights and data.”

Presentation titles featuring authors

The understanding of Peyronie’s disease via a women’s health lens titled ‘A survey of women’s sexual health provider practices and awareness’. This presentation was made by MS Sheryl Kingsberg, Phd, Irwin Goldstein, MD; Rose Hartzell-Cushanick, phd, eds; Becky Lynn, MD; David Hurley, MD; Nicole Tay, MS; Alyse Kelly-jones, MD; Sameena Rahman, MD; Tami Rowen, MD, and Sue W. Goldstein, CSE, CCRC, IF.

Further, the presentations' titles are: ‘Results of a survey of men’s healthcare providers (HCPs); ‘updated results from a noninterventional, retrospective, multicentre study’; and ‘a post Hoc analysis of the IMPRESS 1/2 studies’ featured under sponsored endo portfolio. The authors of these presentations are mentioned on the official Biospace website.

Other presentation based on investigator-initiated research covers Peyronie’s disease clinical outcomes, the advanced practice providers' take on men’s health content in the academic program curricula, and the impact of Peyronie’s disease on female partners (qualitative analysis). Including a comparative study of collagenase histolyticum to surgery for the management of Peyronie’s disease (randomized trial – 3-year outcomes) and efficacy rate of a novel collagenase clostridium histolyticum protocol for Peyronie’s disease among prior non-responders (single-blinded, randomized, controlled study).